Inhaler device plays an important role for the patients‘ QOL to be improved by switching from short-acting anticholinergics to once-daily bronchodilator tiotropium in COPD

N. Chohnabayashi, N. Nishimura, N. Uchiyama, H. Ueda, H. Ono, R. Sugiura, J. Kizu, K. Watanabe, T. Inoue (Tokyo, Japan)

Source: Annual Congress 2006 - Update on treatment of COPD II
Session: Update on treatment of COPD II
Session type: Thematic Poster Session
Number: 2505
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Chohnabayashi, N. Nishimura, N. Uchiyama, H. Ueda, H. Ono, R. Sugiura, J. Kizu, K. Watanabe, T. Inoue (Tokyo, Japan). Inhaler device plays an important role for the patients‘ QOL to be improved by switching from short-acting anticholinergics to once-daily bronchodilator tiotropium in COPD. Eur Respir J 2006; 28: Suppl. 50, 2505

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 215s
Year: 2006

NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 527s
Year: 2006

Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013


Safety of as-needed formoterol in asthma patients on different maintenance long-acting ß2-agonists
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021


Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017


Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015



Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014

Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use
Source: Eur Respir J 2004; 24: Suppl. 48, 289s
Year: 2004

Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients
Source: Annual Congress 2010 - COPD: management
Year: 2010


Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013



Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017


Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 52s
Year: 2002